Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Brain Dev ; 43(2): 230-233, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-856505

ABSTRACT

BACKGROUND: Reversible splenial lesion syndrome (RESLES) is characterized by a temporary lesion in the splenium of the corpus callosum, emerging related to encephalitis, seizures, antiepileptic drug withdrawal, or metabolic disturbances. Among RESLES, mild encephalitis/encephalopathy with reversible splenial lesion (MERS) has been defined as a distinct clinicoradiologic syndrome associated with viral infections. CASE PRESENTATION: We report two children with multisystem inflammatory syndrome-children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who developed RESLES during the disease course. Encephalopathy was the main central nervous system symptom. Both of the children showed a rapid recovery, and brain magnetic resonance imaging revealed complete resolution of the splenial lesion within 1 week. CONCLUSION: The complete resolution of the splenial lesion and rapid recovery from encephalopathy in RESLES associated with SARS CoV-2 were similar to observed in MERS.


Subject(s)
Brain Diseases/diagnostic imaging , COVID-19/diagnosis , Corpus Callosum/diagnostic imaging , Systemic Inflammatory Response Syndrome/diagnostic imaging , Brain Diseases/drug therapy , Brain Diseases/physiopathology , COVID-19/diagnostic imaging , COVID-19/physiopathology , Child , Dyspnea/physiopathology , Electroencephalography , Exanthema/physiopathology , Female , Fever/physiopathology , Glucocorticoids/therapeutic use , Hallucinations/physiopathology , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Magnetic Resonance Imaging , Male , Methylprednisolone/therapeutic use , Neurocognitive Disorders/diagnostic imaging , Neurocognitive Disorders/physiopathology , SARS-CoV-2 , Systemic Inflammatory Response Syndrome/drug therapy , Systemic Inflammatory Response Syndrome/physiopathology , Tachypnea/physiopathology , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL